ACE inhibitor (Enalapril 2.5-40mg/day (uptitrated as tolerated) vs placebo, severe heart failure

Study population:

Patients with severe heart failure  (NYHA class IV).

Co-morbidities included coronary heart disease, previous MI ,  hypertension and diabetes

Comments:

Mean age of patients was 70 years

Symptomatic improvement  was observed i.e. A significant improvement in NYHA classification

NB Patient numbers in the study were low (n=253)